<DOC>
	<DOCNO>NCT02017457</DOCNO>
	<brief_summary>The present project multicenter , phase II trial aim evaluate administration azacytidine ( Vidaza® ) combine donor lymphocyte infusion ( DLI ) could improve response rate DLI population patient relapse acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) allogeneic hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Azacytidine Lymphocytes Relapse AML MDS After Allogeneic Stem Cell Transplantation .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Patients : Age ≥ 18 year Be able understand sign inform consent Fertile patient must use reliable contraception method 2 . Disease status transplantation : AML first subsequent complete remission ( &lt; 5 % marrow blast ) MDS le 10 % marrow blast time transplantation 3 . Transplantation : Allogeneic transplantation use sibling unrelated donor match 10/10 allele ( HLAA , B , C , DRB1 , DQB1 ) maximum one allele one antigen 1 antigen + 1 allele 1 antigen + 1 DQB1 antigen 2 allele mismatch . Myeloablative reducedintensity condition Second transplantation allow Donor willing donate lymphocytes 4 . Clinical situation : Cytological relapse alloSCT define recurrence 5 % blast bone marrow aspiration ( AML ) evidence MDS Immunophenotypic relapse define recurrence abnormal phenotype flow cytometry bone marrow aspirate ( case specific phenotype ) . Cytogenetic molecular relapse define persistence recurrence cytogenetic abnormality molecular marker bone marrow aspiration peripheral blood . WT1 expression consider reliable marker relapse protocol FLT3ITD , NPM1 , CEBPA , translocationspecific marker ( MLLPTD , AMLETO , CBFBMYH11 ) . 5 . Immunosuppressive therapy stop inclusion . More 30 % marrow blast time inclusion Extramedullary relapse include CNS involvement ECOG Performance status &gt; 2 Active acute grade IIIV GvHD time inclusion Active chronic GvHD require systemic therapy time inclusion Uncontrolled infection HIV positive Acute chronic heart failure ( NYHA class III IV ) symptomatic ischemic heart disease ejection fraction &lt; 35 % uncontrolled arrhythmia Severe liver failure ( total bilirubin &gt; 3 mg/dL , SGPT &gt; 4 X upper normal limit ) Severe pulmonary failure ( correct DLCo &lt; 35 % ) Terminal renal failure require dialysis Severe neurological psychiatric disorder Concurrent investigational drug . Other treatment relapse , except hydroxyurea stop inclusion study . Female pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hematology</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplasic syndrome</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>Donor lymphocyte infusion</keyword>
	<keyword>DLI</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Overall response rate</keyword>
	<keyword>Relapse</keyword>
</DOC>